Articles On Cynata Therapeutics (ASX:CYP)
Title | Source | Codes | Date |
---|---|---|---|
ASX 200 closes in green; IT leads gain
Highlights The ASX 200 benchmark index closed in green today (November 11), gaining 194.00 points or 2.79% to end at 7,158.00 points. Over the last five days, the index has gained 3.85% but is down 3.85% for the last year to date. IT... |
Kalkine Media | CYP | 1 year ago |
Cynata Therapeutics (ASX:CYP) receives notice of allowance for Cynata US patent
Cynata Therapeutics (CYP) receives notice of allowance for a patent application covering its Cymerus mesenchymal stem cell (MSC) platform technologyA notice of allowance is sent to an applicant when the United States Patent and Trademark Of... |
themarketherald.com.au | CYP | 1 year ago |
ASX Health Stocks: Patent updates from Cynata and Proteomics; Ramsay sees good times ahead
Cynata gets Notice of Allowance from US Patent Office Proteomics secures patent in Hong Kong Ramsay Healthcare and Avita gave solid quarterly updates Cynata and Proteomics’ patents update Cynata Therapeutics (ASX:CYP) rose 8pc this mornin... |
Stockhead | CYP | 1 year ago |
LUMC to Fund New Clinical Trial of Cynata’s Cymerus™ MSCs in Kidney Transplantation
Key Highlights: Cynata to collaborate with Leiden University Medical Center (LUMC) in the Netherlands, in a new clinical trial in patients who have received a kidney transplant Trial to be funded by LUMC; Cynata will supply iPSC-derived C... |
FNArena | CYP | 1 year ago |
Cynata Therapeutics (ASX:CYP) granted funding for kidney transplantation clinical trial
Cynata Therapeutics (CYP) receives funding for its new clinical trial of Cymerus MSCs for kidney transplantationThe Leiden University Medical Centre (LUMC) agreed to fund the clinical trial investigating Cynata’s Cymerus MSCs as a treatment... |
themarketherald.com.au | CYP | 1 year ago |
ASX Biotech Stocks: HitIQ nabs landmark deal with Premier League for its concussion management tech
HitIQ has entered into a two-year deal with the Premier League for its concussion management tech Hearing-aid manufacturer Nuheara has been awarded two US patents Argentica Therapeutics moves to second escalated dose cohort for its stroke... |
Stockhead | CYP | 1 year ago |
ASX Health Stocks: Patrys crosses brain barrier, opens up possibilities for its deoxymab antibody
Patrys crosses blood brain barrier in health animals Cynata receives Notice of Acceptance from IP Australia Telix announces collaboration with GE Healthcare Patrys (ASX:PAB) surged 15% this morning after announcing that its full-sized deo... |
Stockhead | CYP | 1 year ago |
Cynata Therapeutics (ASX:CYP) successfully completes planned DSMB review of DFU trial
Cynata Therapeutics (CYP) reveals an independent data safety monitoring board (DSMB) completes its review of the company’s diabetic foot ulcer (DFU) trialFollowing the review, the DSMB recommended that the clinical trial continue as planned... |
themarketherald.com.au | CYP | 1 year ago |
ASX Health Stocks: Cynata races ahead after getting green light for diabetic foot ulcer clinical trial
Cynata gets green light for clinical trial from an independent review Apiam acquires large vet business in WA Cynata Therapeutics (ASX:CYP) shares surged 6% after the company announced that an independent review of its diabetic foot ulcer... |
Stockhead | CYP | 1 year ago |
Check Up: Blood clots are a $55bn opportunity and these 2 ASX stocks are vying for a slice
Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re... |
Stockhead | CYP | 1 year ago |
Grant makes Cynata stem cells focus of heart disease study
St Vincent’s Institute of Medical Research has been awarded about $1m to investigate mesenchymal stem cells generated through Cynata Therapeutics’ proprietary Cymerus method as a treatment for heart disease. |
The West | CYP | 1 year ago |
Cynata Therapeutics (ASX:CYP) flags $1m grant for Cymerus MSCs research project
Cynata Therapeutics (CYP) is set to investigate its Cymerus mesenchymal stem cells (MSCs) as a treatment for ischaemic heart disease (IHD) thanks to a $1 million grant from the Australian governmentThe National Health and Medical Research C... |
themarketherald.com.au | CYP | 1 year ago |
ASX Health Stocks: Botanix seeks nod from US FDA; PainChek goes big in Japan
Botanix submits NDA to the US FDA Pharmaxis reports on latest clinical trials PainChek to expand to Japan Clinical dermatology company Botanix Pharma (ASX:BOT) has submitted a New Drug Application (NDA) to the US FDA for Sofpironium Bromi... |
Stockhead | CYP | 1 year ago |
Grant to support cardiovascular study of Cynata Therapeutics' cell therapy
The federal government's National Health and Medical Research Council will provide a $1 million grant to cell therapy company Cynata Therapeutics (ASX:CYP) under its Cardiovascular Health Mission. |
BiotechDispatch | CYP | 1 year ago |
Cynata Therapeutics appoints new non-executive director
Cell therapy company Cynata Therapeutics (ASX:CYP) has announced the appointment of Janine Rolfe as an independent non-executive director. |
BiotechDispatch | CYP | 1 year ago |
ASX Health Stocks: Avita tumbles 16pc as RECELL study results disappoint investors
Avita Medical’s top line results on RECELL disappoint investors Cynata has completed a strategic review, and will terminate its Covid-19 study Resmed’s revenue grows in FY22 Shares in regenerative cells biotech Avita Medical (ASX:AVH) plu... |
Stockhead | CYP | 1 year ago |
Cynata Therapeutics (ASX:CYP) to conclude MEND trial following strategic review
Cynata Therapeutics (CYP) completes a strategic review of its clinical development pipeline to maximise commercial opportunities As a result, it will conclude the current MEND respiratory distress clinical trial as COVID-19 patients admitt... |
themarketherald.com.au | CYP | 1 year ago |
Check Up: US FDA approves first clinical trial of naturally derived psychedelic drugs
US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F... |
Stockhead | CYP | 1 year ago |
Cynata Therapeutics (ASX:CYP) receives notice of allowance for Cynata patent
Cynata Therapeutics (CYP) receives a notice of allowance for its Cymerus mesenchymal stem from the United States Patent and Trademark Office Cymerus mesenchymal stem cell technology for treating asthma and allergic airways disease The comp... |
themarketherald.com.au | CYP | 1 year ago |
ASX Health Stocks: Another Aussie biotech gets attention in the US with a pending patent
Cynata receives notice from the US Patent Office GTG completes acquisition of AffinityDNA Dental clinic network Pacific Smiles announces earnings guidance Cell therapeutics specialist, Cynata Therapeutics (ASX:CYP), has just received a No... |
Stockhead | CYP | 1 year ago |
Cynata Therapeutics secures US patent for Use of the Cymerus MSCs in Asthma
Cell therapy company Cynata Therapeutics (ASX:CYP) has secured a US patent covering the use of its Cymerus mesenchymal stem cell technology in treating asthma and allergic airways disease. |
BiotechDispatch | CYP | 1 year ago |
Check Up: These biotech themes got billions in VC funding. These ASX stocks could benefit
A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m... |
Stockhead | CYP | 1 year ago |
SXG, NST, NCM: Look at the performance of these gold stocks on ASX
Highlights Gold prices fell sharply as the strong US dollar and rise in Treasury yields put pressure on the yellow metal. The S&P/ASX 200 Materials (Sector) XMJ was 0.323% lower at 17866.600 points on ASX at 4:12 PM AEST today. Sh... |
Kalkine Media | CYP | 1 year ago |
Sydney hospital joins Cynata respiratory trial
Cynata Therapeutics, a Melbourne biotechnology company specialising in stemcell therapeutics, has linked with Sydney’s St George Hospital for a clinical trial of its proprietary respiratory product CYP-001. |
The West | CYP | 1 year ago |
Cynata Therapeutics adds new site for MEND clinical trial
Australian cell therapy company Cynata Therapeutics (ASX:CYP) has announced that St George Hospital in Sydney is now a participating site and is seeking to recruit patients in the MEND clinical trial. |
BiotechDispatch | CYP | 1 year ago |
US FDA Clears IND for Cynata’s Phase 2 Clinical Trial of CYP-001 in GvHD
Key Highlights: US FDA has cleared Cynata’s IND application for a Phase 2 clinical trial of CYP-001 in patients with aGvHD – a major milestone and value catalyst for the Company Phase 2 clinical study in aGvHD expected to commence subseque... |
FNArena | CYP | 1 year ago |
Cynata gets go-ahead for US stemcell trial
Melbourne-based stemcell biotechnology company Cynata Therapeutics has got the green light from the USA’s Food and Drug Administration for a clinical trial to combat the deadly graft-versus-host disease. |
The West | CYP | 1 year ago |
Cynata Therapeutics (ASX:CYP) given go-ahead for Phase 2 clinical trial of CYP-001
Cynata Therapeutics (CYP) receives approval from the US Food and Drug Administration (FDA) to commence its Phase 2 clinical trial of CYP-001 CYP-001 is the company’s lead product aimed at treating patients with acute graft versus host dise... |
themarketherald.com.au | CYP | 1 year ago |
Check Up: Money managers are still bullish on Healthcare; here’s what they said
The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week Dr Anthony Faucci, America’s top infectious disea... |
Stockhead | CYP | 1 year ago |
Cynata starts trials on diabetic foot ulcer treatment
Cynata Therapeutics has started clinical trials of its patented polymer-coated silicon wound dressing, a product dosed with its unique Cymerus mesenchymal stem cells, aimed at treating diabetic foot ulcers. |
The West | CYP | 1 year ago |
Check Up: Biotechs are going through a rough patch, but recent ASX IPOs haven’t flopped too badly
The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot... |
Stockhead | CYP | 1 year ago |
Check Up: More clinical trials and FDA funding boost. Is this the end of biotech’s woes?
Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve... |
Stockhead | CYP | 1 year ago |
Check Up: The future of telehealth, and the best and worst performing ASX health stocks for the month
Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal... |
Stockhead | CYP | 2 years ago |
Cynata set for Chinese stem cell patent
China’s patent office has advised cell therapeutics biotech Cynata Therapeutics that it will be given a patent covering its proprietary Cymerus™ mesenchymal stem cell technology. |
The West | CYP | 2 years ago |
Check Up: Johnson & Johnson manoeuvre causes a stir, as CSL pulls Healthcare higher on the ASX
The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby... |
Stockhead | CYP | 2 years ago |
Diagnostic stock Atomo soars 12pc after scoring RAT distribution rights in New Zealand
Australian medical device company and global supplier of rapid diagnostic testing devices (RDT), Atomo (ASX: AT1) has scored distribution rights for rapid antigen tests in New Zealand, after being authorised by the New Zealand Ministry of H... |
Stockhead | CYP | 2 years ago |
Cynata strengthens IP as Japanese deals loom
Stem cell biotech business Cynata Therapeutics is boosting its IP protection after being advised it will shortly be granted a Japanese patent for its proprietary Cymerus regenerative stem cell technology. |
The West | CYP | 2 years ago |
Cynata Therapeutics scoops bumper R&D incentive
Cynata Therapeutics has lopped over $800,000 off its tax bill after the company’s cutting-edge cell therapeutic work was deemed eligible for the Federal Government’s research and development incentive. |
The West | CYP | 2 years ago |
‘Bring in the bulldozers’: Cynata’s CEO on how heavyweight FujiFilm will turbocharge its stem cells production
Stem cell therapy, sometimes called regenerative medicine, is one of the most exciting areas of the life sciences sector right now. It has emerged as a promising alternative approach in many medicine specialties, with some even saying that... |
Stockhead | CYP | 2 years ago |
Check Up: As Omicron rages, rapid antigen testing specialist Atomo surges nearly 50pc
At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform... |
Stockhead | CYP | 2 years ago |
Cynata secures manufacturing deal for breakthrough biotech
Cynata Therapeutics has secured a manufacturing services agreement with specialised human cell manufacturing heavyweight, Fujifilm Cellular Dynamics, to produce Cynata’s Cymerus therapeutic stem cell products. |
The West | CYP | 2 years ago |
Here’s why the Cynata (ASX:CYP) share price is rising today
The Cynata Therapeutics Limited (ASX: CYP) share price is in the green today following news of a company deal. Shares in the biotechnology company are up 4.1%, trading at 50 cents at the time of writing. Let’s look at what might be impact... |
Motley Fool | CYP | 2 years ago |
Cynata Therapeutics (ASX:CYP) signs deal with FUJIFILM Cellular Dynamics
Cynata Therapeutics (CYP) executes a manufacturing services agreement with FUJIFILM Cellular Dynamics (FCDI) for its Cymerus therapeutic mesenchymal stem cell products The agreement sees FCDI undertaking the product’s technology transfer,... |
themarketherald.com.au | CYP | 2 years ago |
Check Up: Anteotech riding high with $1.9m refund, and Avecho inks supply agreement for CBD arthritis treatment
It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining. Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %... |
Stockhead | CYP | 2 years ago |
Cynata launches diabetic foot ulcer clinical trial
Cynata Therapeutics has launched a clinical trial on its Cymerus mesenchymal stem cell product used to treat diabetic foot ulcers in humans. The trial will evaluate safety, wound healing, pain and life quality. |
The West | CYP | 2 years ago |
Cynata Therapeutics (ASX:CYP) commences DFU clinical trial
Cynata Therapeutics (CYP) has commenced a clinical trial of its dressing technology (CYP-006TK) in patients with diabetic foot ulcers (DFU) CYP-006TK is a novel polymer-coated silicon wound dressing, seeded with Cymerus mesenchymal stem ce... |
themarketherald.com.au | CYP | 2 years ago |
Healthcare has been a hot sector. Here are the top ASX biotech stocks in 2021
The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19 ravaged the world. Nasdaq-listed BioNTech, which... |
Stockhead | CYP | 2 years ago |
Check Up: Neuren close to FDA drug approval and Compumedics fires up Aussie factory for medical wearables
It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining. Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont... |
Stockhead | CYP | 2 years ago |
Check Up: Sustainable Nutrition riding high and Singular Health branches out from… health
It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining. Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M... |
Stockhead | CYP | 2 years ago |
Cynata edges closer to diabetic ulcer clinical trial
Cynata Therapeutics has taken a vital step to conducting a clinical trial on its Cymerus product used to treat diabetic foot ulcers, as it looks to enter a market that could be worth US$10 billion by 2027. |
The West | CYP | 2 years ago |